Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers.

Hogan RE, Gidal BE, Koplowitz B, Koplowitz LP, Lowenthal RE, Carrazana E.

Epilepsia. 2020 Feb 17. doi: 10.1111/epi.16449. [Epub ahead of print]

PMID:
32065672
2.

Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.

Klein P, Tolbert D, Gidal BE.

Epilepsy Behav. 2019 Oct;99:106459. doi: 10.1016/j.yebeh.2019.106459. Epub 2019 Sep 10.

PMID:
31519475
3.

Vitamin D abnormalities and bone turn over analysis in children with Epilepsy in the Western Cape of South Africa.

Kija E, Gidal BE, Shapson-Coe A, Cader S, van der Watt G, Delport S, Wilmshurst JM.

Seizure. 2019 Dec;73:84. doi: 10.1016/j.seizure.2019.07.018. Epub 2019 Aug 13. No abstract available.

PMID:
31420230
4.

Vitamin D abnormalities and bone turn over analysis in children with epilepsy in the Western Cape of South Africa.

Kija E, Gidal BE, Shapson-Coe A, Cader S, van der Watt G, Delport S, Wilmshurst JM.

Seizure. 2019 Jul;69:186-192. doi: 10.1016/j.seizure.2019.04.020. Epub 2019 Apr 29.

PMID:
31075750
5.

Lamotrigine and hemophagocytic lymphohistiocytosis.

Meador KJ, Gidal BE.

Neurology. 2019 May 21;92(21):979-980. doi: 10.1212/WNL.0000000000007518. Epub 2019 Apr 17. No abstract available.

PMID:
30996062
6.

Potential protein-binding displacement interactions with perampanel: An in vitro analysis.

Gidal BE, Ferry J, Laurenza A, Ueno T.

Epilepsy Res. 2019 Jan;149:102-106. doi: 10.1016/j.eplepsyres.2018.12.003. Epub 2018 Dec 12.

PMID:
30580179
7.

Summary of Antiepileptic Drugs Available in the United States of America: WORKING TOWARD A WORLD WITHOUT EPILEPSY.

Vossler DG, Weingarten M, Gidal BE; American Epilepsy Society Treatments Committee.

Epilepsy Curr. 2018 Jul-Aug;18(4 Suppl 1):1-26. doi: 10.5698/1535-7597.18.4s1.1. No abstract available.

8.

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Gidal BE, Jacobson MP, Ben-Menachem E, Carreño M, Blum D, Soares-da-Silva P, Falcão A, Rocha F, Moreira J, Grinnell T, Ludwig E, Fiedler-Kelly J, Passarell J, Sunkaraneni S.

Acta Neurol Scand. 2018 Sep;138(3):203-211. doi: 10.1111/ane.12950. Epub 2018 May 6.

9.

Time course of reversal of valproate-mediated inhibition of lamotrigine.

Leary E, Sheth RD, Gidal BE.

Seizure. 2018 Apr;57:76-79. doi: 10.1016/j.seizure.2018.03.003. Epub 2018 Mar 7.

10.

Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.

Mintzer S, Wechsler RT, Rogin JB, Gidal BE, Schwab M, Ben-Menachem E, Carreño M, da Silva PS, Moreira J, Li Y, Blum D, Grinnell T.

Epilepsy Res. 2018 Mar;141:83-89. doi: 10.1016/j.eplepsyres.2018.02.001. Epub 2018 Feb 9.

11.

Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.

Isojarvi J, Gidal BE, Chung S, Wechsler RT.

Epilepsy Behav. 2018 Jan;78:149-154. doi: 10.1016/j.yebeh.2017.10.003. Epub 2017 Dec 22.

12.

When adverse effects are seen as desirable: Abuse potential of the newer generation antiepileptic drugs.

Hawkins KL, Gidal BE.

Epilepsy Behav. 2017 Dec;77:62-72. doi: 10.1016/j.yebeh.2017.10.007. Epub 2017 Nov 5. Review.

PMID:
29111505
13.

Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.

Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ Jr, Jiang W, Jiang X, Switzer RD, Privitera MD.

JAMA Neurol. 2017 Aug 1;74(8):919-926. doi: 10.1001/jamaneurol.2017.0497.

14.

Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.

Gidal BE, Mintzer S, Schwab M, Schutz R, Kharidia J, Blum D, Grinnell T, Sunkaraneni S.

Epilepsy Res. 2017 Sep;135:64-70. doi: 10.1016/j.eplepsyres.2017.05.005. Epub 2017 May 18.

PMID:
28624574
15.

Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.

Gidal BE, Maganti R, Laurenza A, Yang H, Verbel DA, Schuck E, Ferry J.

Epilepsy Res. 2017 Aug;134:41-48. doi: 10.1016/j.eplepsyres.2017.04.018. Epub 2017 Apr 26.

16.

The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate.

Gidal BE, Clark AM, Anders B, Gilliam F.

Epilepsy Res. 2017 Jan;129:26-32. doi: 10.1016/j.eplepsyres.2016.10.020. Epub 2016 Nov 9.

17.

Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.

Gidal BE, Wechsler RT, Sankar R, Montouris GD, White HS, Cloyd JC, Kane MC, Peng G, Tworek DM, Shen V, Isojarvi J.

Neurology. 2016 Oct 25;87(17):1806-1812. Epub 2016 Sep 28.

18.

Cannabidiol and Epilepsy: Sifting, Winnowing and Buzz.

Gidal BE.

Epilepsy Curr. 2016 Jul-Aug;16(4):239-41. doi: 10.5698/1535-7511-16.4.239. No abstract available.

19.

Assessing bioequivalence of generic modified-release antiepileptic drugs.

Johnson EL, Chang YT, Davit B, Gidal BE, Krauss GL.

Neurology. 2016 Apr 26;86(17):1597-604. doi: 10.1212/WNL.0000000000002607. Epub 2016 Mar 25. Erratum in: Neurology. 2016 Jul 26;87(4):447.

20.

Generic Substitution of AEDs: Is it Time to Put This Issue to Rest?

Gidal BE.

Epilepsy Curr. 2016 Jan-Feb;16(1):18-20. doi: 10.5698/1535-7597-16.1.18. No abstract available.

21.

Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.

Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ Jr, Jiang W, Jiang X, Berg M.

Lancet Neurol. 2016 Apr;15(4):365-72. doi: 10.1016/S1474-4422(16)00014-4. Epub 2016 Feb 12.

PMID:
26875743
22.

Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.

Kwan P, Brodie MJ, Laurenza A, FitzGibbon H, Gidal BE.

Epilepsy Res. 2015 Nov;117:117-24. doi: 10.1016/j.eplepsyres.2015.09.002. Epub 2015 Sep 9.

23.

Seeking the Rational (or at least avoiding the irrational).

Gidal BE.

Epilepsy Curr. 2015 Sep-Oct;15(5):260-2. doi: 10.5698/1535-7511-15.5.260. No abstract available.

24.

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.

Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE.

Epilepsia. 2015 Nov;56(11):1723-31. doi: 10.1111/epi.13131. Epub 2015 Sep 2.

25.

Phenytoin Hypersensitivity: It's Time for Some Individuality.

Gidal BE.

Epilepsy Curr. 2015 Jul-Aug;15(4):177-9. doi: 10.5698/1535-7511-15.4.177. No abstract available.

26.

Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.

Gefroh-Grimes HA, Gidal BE.

Acta Neurol Scand. 2016 Jan;133(1):4-16. doi: 10.1111/ane.12437. Epub 2015 May 21. Review.

PMID:
25996875
27.

Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.

Gidal BE, Laurenza A, Hussein Z, Yang H, Fain R, Edelstein J, Kumar D, Ferry J.

Neurology. 2015 May 12;84(19):1972-80. doi: 10.1212/WNL.0000000000001558. Epub 2015 Apr 15.

28.

Cannabidiol: promise and pitfalls.

Welty TE, Luebke A, Gidal BE.

Epilepsy Curr. 2014 Sep;14(5):250-2. doi: 10.5698/1535-7597-14.5.250.

29.

P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence?

Gidal BE.

Epilepsy Curr. 2014 May;14(3):136-8. doi: 10.5698/1535-7597-14.3.136. No abstract available.

30.

The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.

Gidal BE, Majid O, Ferry J, Hussein Z, Yang H, Zhu J, Fain R, Laurenza A.

Epilepsy Behav. 2014 Jun;35:6-12. doi: 10.1016/j.yebeh.2014.03.013. Epub 2014 Apr 27.

PMID:
24785428
31.

Evaluation of the performance improvement CME paradigm for pain management in the long-term care setting.

Fine PG, Bradshaw DH, Cohen MJ, Connor SR, Donaldson G, Gharibo C, Gidal BE, Muir JC, Tselentis HN.

Pain Med. 2014 Mar;15(3):403-9. doi: 10.1111/pme.12339. Epub 2014 Jan 14.

PMID:
24423103
32.

Serotonin and epilepsy: the story continues.

Gidal BE.

Epilepsy Curr. 2013 Nov;13(6):289-90. doi: 10.5698/1535-7597-13.6.289. No abstract available.

33.

Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.

Diaz FJ, Berg MJ, Krebill R, Welty T, Gidal BE, Alloway R, Privitera M.

Clin Pharmacokinet. 2013 Dec;52(12):1033-43. doi: 10.1007/s40262-013-0103-4.

PMID:
24085600
34.

Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.

Gidal BE, Ferry J, Majid O, Hussein Z.

Epilepsia. 2013 Aug;54(8):1490-7. doi: 10.1111/epi.12240. Epub 2013 Jun 17.

35.

QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy.

Feldman AE, Gidal BE.

Epilepsy Behav. 2013 Mar;26(3):421-6. doi: 10.1016/j.yebeh.2012.09.021. Epub 2012 Dec 4. Review.

PMID:
23218812
36.

Enzyme induction with antiepileptic drugs: cause for concern?

Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D.

Epilepsia. 2013 Jan;54(1):11-27. doi: 10.1111/j.1528-1167.2012.03671.x. Epub 2012 Sep 27. Review.

37.

Vigabatrin-associated retinal damage: potential biochemical mechanisms.

Heim MK, Gidal BE.

Acta Neurol Scand. 2012 Oct;126(4):219-28. doi: 10.1111/j.1600-0404.2012.01684.x. Epub 2012 May 26. Review.

PMID:
22632110
38.

Generic antiepileptic drugs: how good is close enough?

Gidal BE.

Epilepsy Curr. 2012 Jan;12(1):32-4. doi: 10.5698/1535-7511-12.1.32. No abstract available.

39.

Carbamazepine hypersensitivity: progress toward predicting the unpredictable.

Gidal BE.

Epilepsy Curr. 2011 Nov;11(6):189-91. doi: 10.5698/1535-7511-11.6.189. No abstract available.

40.

Pharmacokinetic interactions with antiepileptic drugs: always the bad actor or simply misunderstood?

Gidal BE.

Epilepsy Curr. 2010 Sep;10(5):113-5. doi: 10.1111/j.1535-7511.2010.01374.x. No abstract available.

41.

The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.

Candrilli SD, Manjunath R, Davis KL, Gidal BE.

Epilepsy Res. 2010 Oct;91(2-3):260-6. doi: 10.1016/j.eplepsyres.2010.07.021.

PMID:
20801617
42.

The effect of carbapenem antibiotics on plasma concentrations of valproic acid.

Mancl EE, Gidal BE.

Ann Pharmacother. 2009 Dec;43(12):2082-7. doi: 10.1345/aph.1M296. Epub 2009 Nov 24. Review.

PMID:
19934386
43.

Bioequivalence of antiepileptic drugs: how close is close enough?

Gidal BE.

Curr Neurol Neurosci Rep. 2009 Jul;9(4):333-7. Review.

PMID:
19515287
44.

Assessment of potential drug interactions in patients with epilepsy: impact of age and sex.

Gidal BE, French JA, Grossman P, Le Teuff G.

Neurology. 2009 Feb 3;72(5):419-25. doi: 10.1212/01.wnl.0000341789.77291.8d.

PMID:
19188572
45.

Debate: Substitution of generic drugs in epilepsy: is there cause for concern?

Gidal BE, Tomson T.

Epilepsia. 2008 Dec;49 Suppl 9:56-62. doi: 10.1111/j.1528-1167.2008.01927.x. Review.

46.

Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs.

Kanner AM, Gidal BE.

Int Rev Neurobiol. 2008;83:397-416. doi: 10.1016/S0074-7742(08)00022-6. Review.

PMID:
18929094
47.

Epilepsy in women.

Gidal BE, Harden CL.

Int Rev Neurobiol. 2008;83:xvii-xviii. doi: 10.1016/S0074-7742(08)00027-5. No abstract available.

PMID:
18929072
48.

Pharmacology of antiepileptic drugs during pregnancy and lactation.

Pennell PB, Gidal BE, Sabers A, Gordon J, Perucca E.

Epilepsy Behav. 2007 Nov;11(3):263-9. Review.

PMID:
17996633
49.

Conversions between monotherapies in epilepsy: expert consensus.

St Louis EK, Gidal BE, Henry TR, Kaydanova Y, Krumholz A, McCabe PH, Montouris GD, Rosenfeld WE, Smith BJ, Stern JM, Waterhouse EJ, Schulz RM, Garnett WR, Bramley T.

Epilepsy Behav. 2007 Sep;11(2):222-34. Epub 2007 Jun 22.

PMID:
17586097
50.

Supplemental Content

Loading ...
Support Center